🔍

VAISHALI - Vaishali Pharma

📊 NSE: VAISHALI 🏢 Trading 📅 Last Updated: 12/14/2025 14:53

📢 Recent Corporate Announcements

Vaishali Pharma Clarifies Recent Stock Price Movement as Purely Market Driven

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Apr 2026, 10:18 AM

Vaishali Pharma Limited has responded to a clarification request from the National Stock Exchange regarding significant recent movements in its stock price. In its official statement dated April 22, 2026, the company clarified that there is no undisclosed price-sensitive information or material events that have been withheld from the market. The management asserts that the current price and volume fluctuations are solely attributable to market conditions and are not linked to any internal corporate developments. The company remains in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

Company responded to NSE surveillance query dated April 21, 2026, regarding price movement
Management confirms no undisclosed material information or price-sensitive events exist
Price and volume fluctuations are stated to be 100% market-driven and not internal
Company maintains full compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations

💡 As the company has denied any new material developments, investors should treat the recent price volatility as speculative or market-driven. Focus on fundamental performance rather than short-term price swings that lack corporate catalysts.

Vaishali Pharma Reports 100% Demat Shareholding for Quarter Ended March 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Apr 2026, 03:14 PM

Vaishali Pharma Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The company's Registrar and Share Transfer Agent, Bigshare Services Pvt. Ltd., confirmed that no rematerialization requests were received during the quarter from January 1, 2026, to March 31, 2026. Notably, the entire shareholding of the company is already maintained in dematerialized form. This is a standard procedural filing required by Indian stock exchanges to ensure shareholding integrity.

Compliance certificate issued for the quarter ended March 31, 2026
100% of the company's shares are currently held in dematerialized form
Zero requests for rematerialization were received during the three-month period
Confirmation provided by Registrar and Share Transfer Agent, Bigshare Services Pvt. Ltd.

💡 No action is required from investors as this is a routine regulatory filing confirming the company's compliance with SEBI shareholding norms.

Vaishali Pharma Promoters Confirm Zero Share Encumbrance for FY 2025-26

🟢 POSITIVE ⭐ 4/10

REGULATORY 📅 10 Apr 2026, 05:20 PM

Atul Arvindbhai Vasani, Promoter and CMD of Vaishali Pharma Limited, has submitted a formal disclosure under Regulation 31(4) of SEBI (SAST) Regulations. The filing confirms that the Promoter and Promoter Group, including Persons Acting in Concert (PAC), have not created any direct or indirect encumbrance on their shares during the financial year ended March 31, 2026. This routine annual declaration provides transparency regarding the status of promoter holdings. The absence of pledged shares is generally viewed as a sign of financial stability and promoter confidence.

Annual disclosure submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Promoter group confirms zero encumbrance or pledging of shares for the financial year ended March 31, 2026.
The declaration covers all members of the Promoter Group and Persons Acting in Concert (PAC).
Confirmation provided by Atul Arvindbhai Vasani in his capacity as Promoter and Chairman cum Managing Director.

💡 Investors should note this as a positive indicator of financial health, as unencumbered promoter shares reduce the risk of volatility from margin calls. No immediate action is required as this is a standard annual compliance filing.

Vaishali Pharma Promoters Confirm Zero Share Encumbrance for FY 2025-26

🟢 POSITIVE ⭐ 4/10

REGULATORY 📅 02 Apr 2026, 04:54 PM

Vaishali Pharma Limited has filed its annual disclosure under Regulation 31(4) of SEBI (SAST) Regulations for the financial year ended March 31, 2026. The Promoter and Promoter Group, including Persons Acting in Concert, have confirmed that no shares were encumbered, directly or indirectly, during the period. This routine disclosure provides transparency regarding the status of promoter holdings. It indicates that the promoter's equity remains unpledged, which is a positive indicator of financial stability for the company.

Promoters confirmed zero encumbrance on company shares for the financial year ended March 31, 2026.
Disclosure submitted in compliance with Regulation 31(4) of SEBI (SAST) Regulations, 2011.
The declaration covers the entire Promoter Group and Persons Acting in Concert (PAC).

💡 This is a positive routine update confirming that promoter shares are not pledged. Investors can maintain their current positions as this reinforces the stability of the promoter's stake.

Vaishali Pharma to Close Trading Window from April 1, 2026 for FY26 Audited Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 28 Mar 2026, 03:14 PM

Vaishali Pharma Limited has announced the closure of its trading window effective April 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is mandatory ahead of the consideration and approval of the company's Audited Financial Results for the fiscal year ending March 31, 2026. The restriction applies to all designated persons, including directors and officers, to prevent any potential insider trading. The window will remain closed until 48 hours after the financial results are officially declared to the public.

Trading window closure starts on April 1, 2026.
Closure is for the purpose of finalizing Audited Financial Results for the year ended March 31, 2026.
Trading window will reopen 48 hours after the results are made public.
Restriction applies to all Officers, Designated Employees, Directors, and Auditors of the company.

💡 This is a routine regulatory announcement and requires no immediate action from retail investors. Investors should await the announcement of the audited financial results for performance assessment.

Vaishali Pharma Shareholders Approve Preferential Issue of Equity Shares

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 16 Mar 2026, 07:04 PM

Vaishali Pharma Limited has received shareholder approval through a postal ballot for the issuance and allotment of equity shares on a preferential basis. The special resolution was passed with an overwhelming majority, with 99.99% of the votes cast in favor by participating public shareholders. Promoters and the promoter group abstained from voting as they were interested parties in the resolution. This approval clears the path for the company to raise capital, which is typically used for expansion or strengthening the balance sheet.

Special Resolution for issuing equity shares on a preferential basis was approved by shareholders.
The resolution received 99.9909% votes in favor from the public non-institutional category.
A total of 25,415,321 votes were polled during the postal ballot process.
Promoters and promoter group members abstained from voting due to their interest in the resolution.
The record date for determining eligibility for the postal ballot was February 6, 2026.

💡 Investors should monitor upcoming disclosures regarding the specific allotment price and the list of allottees to evaluate the impact of equity dilution. The successful approval indicates strong shareholder support for the company's fundraising and growth plans.

Vaishali Pharma to Acquire 51.02% of Kesar Pharma; Preferential Issue at Rs 20 Per Share

🟢 POSITIVE ⭐ 8/10

M&A 📅 28 Feb 2026, 08:50 PM

Vaishali Pharma has issued a corrigendum to its postal ballot notice regarding the acquisition of a 51.02% stake in Kesar Pharma Limited. The deal involves a preferential issue of shares at Rs 20 each, which is significantly higher than the SEBI-mandated floor price of Rs 09.46. The floor price was derived from the 90-day volume-weighted average price (VWAP) as per regulatory requirements. Shareholders have until March 15, 2026, to cast or modify their votes based on these updated disclosures.

Proposed acquisition of a 51.02% majority stake in Kesar Pharma Limited
Preferential shares to be issued at Rs 20 per share, a 111% premium over the floor price of Rs 09.46
Floor price based on 90-day VWAP of Rs 09.46 and 10-day VWAP of Rs 08.02
Relevant date for the transaction pricing is February 13, 2026
E-voting facility for shareholders is open until 05:00 PM on March 15, 2026

💡 Investors should monitor the successful integration of Kesar Pharma as it represents a significant majority acquisition. The high issue price relative to the floor price is a positive signal regarding the company's internal valuation.

Vaishali Pharma to Issue 61.23 Lakh Shares for 33.24% Stake in Kesar Pharma

🟢 POSITIVE ⭐ 8/10

M&A 📅 16 Feb 2026, 01:05 PM

Vaishali Pharma Limited has issued a postal ballot notice to seek shareholder approval for a preferential allotment of 61.23 lakh equity shares. The shares are priced at Rs. 20 each, representing a total transaction value of approximately Rs. 12.25 crores. This is a non-cash transaction involving a share swap to acquire a 33.24% stake in Kesar Pharma Limited, an associate company. The e-voting period for shareholders is scheduled from February 14 to March 15, 2026.

Preferential issue of up to 61,23,000 equity shares at an issue price of Rs. 20 per share
Total consideration of Rs. 12.25 crores to be settled via share swap (non-cash)
Acquisition of 21,52,575 shares in Kesar Pharma Limited, representing a 33.24% stake
Relevant date for floor price determination fixed as February 13, 2026
E-voting results to be announced on or before March 17, 2026

💡 Investors should assess the strategic value of consolidating the stake in Kesar Pharma against the equity dilution caused by the new share issuance. Monitor the final approval and subsequent integration of Kesar Pharma's operations.

Vaishali Pharma Approves Rs 12.25 Cr Share Swap for Kesar Pharma Stake

🟡 NEUTRAL ⭐ 7/10

FUNDRAISE 📅 13 Feb 2026, 07:35 PM

Vaishali Pharma has approved the issuance of 61.23 lakh equity shares at Rs 20 each via a preferential allotment. This is a non-cash transaction involving a share swap to acquire 21.52 lakh shares of its associate company, Kesar Pharma Limited, at Rs 56.89 per share. The total value of the issuance is approximately Rs 12.25 Crores, resulting in Kesar Pharma holding a 4.48% stake in the company. Additionally, the board has cleared the unaudited financial results for the quarter and nine months ended December 31, 2025.

Issuance of 61,23,000 equity shares at a price of Rs 20 per share
Total deal value of Rs 12.246 Crores via share swap for Kesar Pharma stake
Acquisition of 21,52,575 shares of Kesar Pharma Limited at Rs 56.89 per share
Post-allotment, Kesar Pharma Limited will own 4.48% of Vaishali Pharma
Board approved Q3 FY26 results and initiated a postal ballot for shareholder approval

💡 Investors should evaluate the valuation of Kesar Pharma and the impact of the 4.48% equity dilution on earnings per share. Watch for the detailed Q3 financial performance to assess the company's growth trajectory.

Vaishali Pharma to Issue 61.23 Lakh Shares via Swap for Kesar Pharma Stake

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 13 Feb 2026, 07:03 PM

Vaishali Pharma has approved a preferential allotment of 61.23 lakh equity shares at an issue price of ₹20 per share, totaling approximately ₹12.25 crores. This is a non-cash transaction executed via a share swap to subscribe to 21.53 lakh shares of its associate company, Kesar Pharma Limited, at ₹56.89 per share. Post-allotment, Kesar Pharma will hold a 4.48% stake in Vaishali Pharma. The board also approved the unaudited financial results for the quarter ended December 31, 2025.

Preferential issue of 61,23,000 equity shares at ₹20 each (including ₹18 premium).
Total transaction value for the share swap is ₹12,24,60,000.
Acquisition of 21,52,575 shares of associate company Kesar Pharma Limited at ₹56.89 per share.
Post-issue, Kesar Pharma Limited will hold a 4.48% equity stake in Vaishali Pharma.
Board approved Q3 FY26 financial results and initiated a Postal Ballot for shareholder approval.

💡 Investors should monitor the strategic benefits of increasing the stake in Kesar Pharma and review the Q3 financial results for operational performance. The share swap indicates a consolidation of interests with its associate company.

Vaishali Pharma to Issue Shares Worth ₹12.25 Cr via Swap for Kesar Pharma Stake

🔵 WATCH ⭐ 7/10

FUNDRAISE 📅 13 Feb 2026, 06:56 PM

Vaishali Pharma's board has approved a preferential allotment of 61.23 lakh equity shares at ₹20 per share, totaling ₹12.25 crore. This is a non-cash transaction executed via a share swap to acquire 21.53 lakh shares of its associate company, Kesar Pharma Limited, at ₹56.89 per share. The board also cleared the unaudited financial results for the quarter ended December 31, 2025. This move will result in Kesar Pharma Limited holding a 4.48% stake in Vaishali Pharma post-allotment.

Issuance of 61,23,000 equity shares at ₹20 per share aggregating to ₹12.246 Crores.
Transaction involves a share swap for 21,52,575 shares of associate company Kesar Pharma.
Kesar Pharma Limited to hold 4.48% post-issue equity in Vaishali Pharma.
Board approved Q3 and 9M FY26 financial results during the same meeting.
Relevant date for floor price determination set as February 13, 2026.

💡 Investors should review the Q3 financial performance and assess the strategic value of increasing the stake in Kesar Pharma. Monitor the upcoming postal ballot results for shareholder approval of this preferential issue.

Vaishali Pharma Clarifies Lack of Comparative Consolidated Financials Due to Kesar Pharma Stake

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 05 Feb 2026, 01:04 PM

Vaishali Pharma Limited has provided a clarification to the National Stock Exchange regarding the absence of comparative figures in its consolidated financial results for the quarter ended September 30, 2025. The company explained that it acquired a 20.3263359% stake in Kesar Pharma Limited on September 10, 2025, making it an associate company. Since this is the first time the company is required to prepare consolidated financials, no prior period comparative data exists. Consequently, the comparative figures for the previous year represent standalone data only.

Acquired 20.3263359% equity shares of Kesar Pharma Limited on September 10, 2025
Kesar Pharma Limited classified as an associate company under Ind AS 28
Consolidated financial results prepared for the first time starting from the current reporting period
Comparative figures for the year ended March 31, 2025, represent standalone balance sheet data
Clarification issued in response to National Stock Exchange observation regarding Regulation 33 of SEBI LODR

💡 Investors should treat the current consolidated figures as a new baseline for the company's expanded operations. Future year-on-year comparisons will only become meaningful once the company completes a full annual cycle with its associate company included.

Vaishali Pharma: 2,32,70,000 Equity Shares Listed on NSE

🟡 NEUTRAL ⭐ 5/10

REGULATORY 📅 09 Dec 2025, 08:25 PM

Vaishali Pharma Limited received approval from NSE for trading of 2,32,70,000 equity shares of ₹2 each. These shares, bearing distinctive numbers from 107192131 to 130462130, were issued to Promoters and Non-Promoters on a preferential basis following the conversion of warrants. The equity shares were listed and admitted to dealings on the Exchange effective December 09, 2025. Investors should note the lock-in periods for specific share ranges as detailed in Annexure I.

2,32,70,000 equity shares of ₹2 each listed on NSE
Shares issued to Promoters and Non-Promoters on preferential basis
Distinctive numbers range from 107192131 to 130462130
Trading commenced on December 09, 2025
Lock-in periods extend up to June 30, 2027 for certain shares

💡 Investors should review the lock-in details in Annexure I to understand any restrictions on trading these newly listed shares. Monitor the trading activity of these shares for any potential impact on the stock price.

View All VAISHALI Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in two primary segments: API (Active Pharmaceutical Ingredients) which contributes 60% of revenue, and Formulations/Surgical/Veterinary which contributes 40%. Revenue from operations grew 14.77% YoY to INR 99.03 Cr in FY25 from INR 86.28 Cr in FY24.

Geographic Revenue Split

Domestic sales account for 50-55% of revenue, while export business contributes 40-45%. The company has a presence in 40+ countries, with strategic partnerships in Russia, Kenya, and D.R. Congo.

Profitability Margins

Net profit margin for 9M FY24 was 9.82% (INR 5.40 Cr). However, for the full year FY25, Profit Before Tax stood at INR 1.23 Cr on a total income of INR 102.23 Cr, representing a PBT margin of approximately 1.2%. The company aims to expand EBITDA margins to 25% within five years by shifting focus to high-margin formulations.

EBITDA Margin

EBITDA margin was 16.45% for 9M FY24 (EBITDA of INR 9.05 Cr) but showed volatility, dipping to 12.05% in Q3 FY24. The company is targeting a long-term sustainable EBITDA margin of 25% through product mix optimization.

Capital Expenditure

Not explicitly disclosed in absolute INR Cr, but the company is actively 'boosting production capacity' and scaling up operations to meet surging demand in international markets.

Credit Rating & Borrowing

Finance costs were INR 1.58 Cr in FY25, a decrease of 8.86% from INR 1.74 Cr in FY24, suggesting improved debt management or lower utilization of credit lines.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) represent the primary raw material for the formulation segment, while stock-in-trade purchases for the trading business accounted for INR 90.10 Cr (91% of revenue) in FY25.

Import Sources

Sourced from domestic and international markets; specific countries are not named, but the company maintains an office in Vietnam and partnerships in Russia and Africa for trade and distribution.

Capacity Expansion

Current warehouse capacity is over 100 tonnes in Bhiwandi, Maharashtra. The company is scaling production capacity to cater to international demand, supported by WHO-GMP, EU-GMP, and USFDA approved facilities.

Raw Material Costs

Purchases of stock-in-trade reached INR 90.10 Cr in FY25, up 25.59% from INR 71.75 Cr in FY24. This high cost-to-revenue ratio reflects the company's significant trading and marketing operations.

Manufacturing Efficiency

The company utilizes WHO-GMP and USFDA approved facilities to ensure high-quality standards, which acts as a barrier to entry and improves acceptance in regulated markets.

Logistics & Distribution

Distribution is handled through a network of 1,000+ customers across 35+ locations globally.

📈 Strategic Growth

Expected Growth Rate

38%

Growth Strategy

The company plans to reach INR 500 Cr revenue in 5 years by shifting the revenue mix from 60% API to a 50/50 split with high-margin formulations. Strategy includes registering new brands in export markets, expanding the veterinary business in Russia, and leveraging the Sankalp Life Care partnership for nutraceuticals.

Products & Services

Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, surgical products (including gloves and medical disposables), veterinary supplements, herbal products, nutraceuticals, and oncology medicines.

Brand Portfolio

Vaishali Pharma, Sankalp Life Care (marketing operations).

New Products/Services

Continuous registration of new brands in the formulation and veterinary segments is expected to drive the margin expansion from 16% to 25%.

Market Expansion

Targeting expansion in Russia (veterinary), Kenya, D.R. Congo, and Vietnam. The company recently participated in CPHI Barcelona to increase global visibility.

Market Share & Ranking

Positioned as a leading player in Russia's veterinary product domain within just two years of entry.

Strategic Alliances

Strategic partnership with Sankalp Life Care to oversee and operate their domestic and international marketing operations for nutraceuticals.

🌍 External Factors

Industry Trends

The industry is shifting toward specialized nutraceuticals and veterinary health. Vaishali is positioning itself by moving from pure API trading to a brand-led formulation model to capture higher value-add.

Competitive Landscape

Competes with both domestic API traders and international formulation players in emerging markets.

Competitive Moat

Moat is built on 'Strong Entry Barriers' created by requisite registrations and certifications (WHO-GMP, USFDA) and a portfolio of 250+ registered brands which are difficult for new entrants to replicate quickly.

Macro Economic Sensitivity

Highly sensitive to global pharmaceutical supply chain shifts and healthcare spending in emerging markets like Africa and CIS countries.

Consumer Behavior

Increased global focus on preventive health is driving demand for the company's herbal and nutraceutical segments.

Geopolitical Risks

Operations in Russia and African nations expose the company to regional geopolitical instability and changes in import regulations.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by WHO-GMP, EU-GMP, and USFDA manufacturing standards. Compliance with diverse regulatory requirements of 40+ countries is mandatory for brand registrations.